American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 533.e1-533.e8 , November 2008

Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary

  • Elin Ødegaard, MD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Ben Davidson, MD, PhD

      Affiliations

    • Faculty of Medicine, University of Oslo, Oslo, Norway
    • Pathology Clinic, Rikshospitalet-Radiumhospitalet Medical Center, Oslo, Norway
    • ,
  • Vibeke Engh, MD

      Affiliations

    • Department of Pathology, Ulleval University Hospital, Oslo, Norway
    • ,
  • Mathias Onsrud, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway
    • ,
  • Anne Cathrine Staff, MD, PhD

      Affiliations

    • Department of Obstetrics and Gynaecology, Ulleval University Hospital, Oslo, Norway
    • Faculty of Medicine, University of Oslo, Oslo, Norway

Received 18 October 2007 ,Revised 12 December 2007 ,Accepted 2 April 2008.

References 

  1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29
  2. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In:  Hoskins WJ,  Perez CA,  Young RC editor. Principles and practice of gynecologic oncology. Philadelphia (PA): Lippincott-Raven; 1997;p. 919–986
  3. Shih I, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges. Clin Cancer Res. 2005;11:7273–7279
  4. Bast RC, Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(Suppl 3):274–281
  5. Odegaard E, Davidson B, Elgaaen BV, et al. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol. 2008;198:418.e1–418.e7
  6. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003;22:6557–6563
  7. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J. 2003;17:984–992
  8. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856–861
  9. Vermeulen PB, Roland L, Mertens V, et al. Correlation of intratumoral microvessel density and p53 protein overexpression in human colorectal adenocarcinoma. Microvasc Res. 1996;51:164–174
  10. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. J Transl Med. 2004;2:18
  11. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas. APMIS. 2003;111:1011–1018
  12. Saad RS, Jasnosz KM, Tung MY, Silverman JF. Endoglin (CD105) expression in endometrial carcinoma. Int J Gynecol Pathol. 2003;22:248–253
  13. Erdem O, Taskiran C, Onan MA, Erdem M, Guner H, Ataoglu O. CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol. 2006;103:1007–1011
  14. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16:1789–1793
  15. Wang JM, Wilson PB, Kumar S, Pye D, Hunter RD. Quantitation of endothelial cell specific protein E-9 employing a single monoclonal antibody in an indirect sandwich ELISA. J Immunol Methods. 1994;171:55–64
  16. Takahashi N, Kawanishi-Tabata R, Haba A, et al. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res. 2001;7:524–532
  17. Li C, Guo B, Wilson PB, et al. Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer. 2000;89:122–126
  18. Beresford MJ, Harris AL, Ah-See M, Daley F, Padhani AR, Makris A. The relationship of the neo-angiogenic marker, endoglin, with response to neoadjuvant chemotherapy in breast cancer. Br J Cancer. 2006;95:1683–1688
  19. Staff AC, Braekke K, Johnsen GM, Karumanchi A, Harsem NK. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum as well as amniotic fluid in preeclampsia. Am J Obstet Gynecol. 2007;176.e1–176.e6
  20. Canevari S, Gariboldi M, Reid JF, Bongarzone I, Pierotti MA. Molecular predictors of response and outcome in ovarian cancer. Crit Rev Oncol Hematol. 2006;60:19–37
  21. Pezzella F, Pastorino U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am J Pathol. 1997;151:1417–1423
  22. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res. 2000;60:1388–1393
  23. Henriksen R, Gobl A, Wilander E, Oberg K, Miyazono K, Funa K. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73:213–220
  24. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642–649
  25. Simak J, Gelderman MP. Cell membrane microparticles in blood and blood products: Potentially pathogenic agents and diagnostic markers. Transfus Med Rev. 2006;20:1–26
  26. Ocana A, Rodriguez-Barbero A, Pericacho M, et al. Human recombinant erythropoietic agents do not induce changes in circulating levels of endoglin and vascular endothelial growth factor in anemic cancer patients. Cancer Lett. 2007;255:71–76

 Cite this article as: Ødegaard E, Davidson B, Engh V, et al. Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary. Am J Obstet Gynecol 2008;199:533.e1-533.e8.

 This study was supported by a research grant from the Regional Health Authority, Eastern Norway (to E.Ø.).

 Reprints not available from the authors.

PII: S0002-9378(08)00395-5

doi: 10.1016/j.ajog.2008.04.004

American Journal of Obstetrics & Gynecology
Volume 199, Issue 5 , Pages 533.e1-533.e8 , November 2008

Article Tools

* Image Usage & Resolution